We are live on ! Find out more
PRVL

Prevail Therapeutics
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

67 hedge funds and large institutions have $421M invested in Prevail Therapeutics in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

17% more capital inflows, than outflows

Capital inflows: $58.3M | Capital outflows: $50M

16% more funds holding

Funds holding: 58 → 67 (+9)

1.2% more ownership

Funds ownership: 81.42% → 82.62% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
67
Holders Change
+9
Holders Change %
+15.52%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
25
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PRVL Hedge Fund Activity: Q2 2020 in Review

67 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics (PRVL) for Q2 2020, worth a combined $421M — up 24% from $339M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PRVL positions and 5 closed out — a net gain of 9 holders — while 25 added to existing stakes and 13 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.8M. The largest seller was EcoR1 Capital, cutting an estimated $29M.

  • 67 institutional investors held Prevail Therapeutics (PRVL) as of Q2 2020, up from 58 in Q1 2020.
  • Funds reported $421M of Prevail Therapeutics stock for Q2 2020, up 24% quarter-over-quarter.
  • 14 funds opened new Prevail Therapeutics positions in Q2 2020 and 5 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics buyer in Q2 2020 was Avidity Partners Management, an estimated $15.8M added.
  • The largest Prevail Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2020.